Cartela Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 2

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $605K

Cartela General Information

Description

Developer of therapies for arthritic diseases. The specializes in the development of therapies in arthritic diseases, primarily osteoarthritis and rheumatoid arthritis.

Contact Information

Website
www.cartela.se
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Box 709
  • Lund
  • Sweden
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Hansa Biopharma
Corporate Office
  • Box 709
  • Lund
  • Sweden

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cartela Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 15-Jan-2008 $605K Completed Generating Revenue
3. Early Stage VC 01-Jan-2005 Completed Startup
2. Early Stage VC 13-Feb-2003 $843K $843K Completed Startup
1. Early Stage VC 01-Jan-2001 Completed Startup
To view Cartela’s complete valuation and funding history, request access »

Cartela Patents

  • 38

    Total Documents Applications and Grants

  • Total Patents Families

  • 7

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

Cartela Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-0625165-D0 Novel binding agents and uses thereof Inactive 18-Dec-2006
CA-2709411-A1 Binding agents to the integrin alpha-11 subunit, and uses thereof Inactive 18-Dec-2006
AU-2007335988-A1 Binding agents to the integrin alpha-11 subunit, and uses thereof Inactive 18-Dec-2006
JP-2010514413-A Binding agent for integrin α-11 subunit and use thereof Pending 18-Dec-2006
EP-2101818-A1 Binding agents to the integrin alpha-11 subunit, and uses thereof Inactive 18-Dec-2006 C07K16/2839
To view Cartela’s complete patent history, request access »

Cartela Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cartela Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Axel Granlund Corporation Minority
Industrifonden Venture Capital Minority
Innovationsbron Venture Capital Minority
Skrindan Corporation Minority
TeknoSeed Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

Cartela FAQs

  • When was Cartela founded?

    Cartela was founded in 2000.

  • Where is Cartela headquartered?

    Cartela is headquartered in Lund, Sweden.

  • What is the size of Cartela?

    Cartela has 2 total employees.

  • What industry is Cartela in?

    Cartela’s primary industry is Drug Discovery.

  • Is Cartela a private or public company?

    Cartela is a Private company.

  • What is the current valuation of Cartela?

    The current valuation of Cartela is .

  • What is Cartela’s current revenue?

    The current revenue for Cartela is .

  • How much funding has Cartela raised over time?

    Cartela has raised $843K.

  • Who are Cartela’s investors?

    Axel Granlund, Industrifonden, Innovationsbron, Skrindan, and TeknoSeed are 5 of 6 investors who have invested in Cartela.

  • When was Cartela acquired?

    Cartela was acquired on 15-Jan-2008.

  • Who acquired Cartela?

    Cartela was acquired by Hansa Biopharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »